The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, PIKfyve, apilimod, LAM-002A, STA-5326, 【초록키워드】 Treatment, clinical trial, Immunosuppression, clinical trials, protease, PIKfyve, T cell, Viral, immune responses, Proteases, Antigen presentation, Critical, apilimod, T cell activation, Evidence, COVID-19 patient, host cell, treatment of COVID-19, clinic, in vitro study, viral invasion, antiviral immune responses, host cell proteases, block, Prevent, inhibiting, PIKfyve inhibitor, 【제목키워드】 Sword,
【저자키워드】 COVID-19, SARS-CoV-2, PIKfyve, apilimod, LAM-002A, STA-5326, 【초록키워드】 Treatment, clinical trial, Immunosuppression, clinical trials, protease, PIKfyve, T cell, Viral, immune responses, Proteases, Antigen presentation, Critical, apilimod, T cell activation, Evidence, COVID-19 patient, host cell, treatment of COVID-19, clinic, in vitro study, viral invasion, antiviral immune responses, host cell proteases, block, Prevent, inhibiting, PIKfyve inhibitor, 【제목키워드】 Sword,
PIKfyve 억제제 아필리모드는 현재 COVID-19 치료를 위한 임상 시험을 진행 중입니다. 그러나 아필리모드가 숙주 세포 프로테아제를 억제하여 바이러스 침입을 예방할 수 있지만 동일한 프로테아제는 T 세포 활성화를 유도하는 항원 제시에 중요하며 아필리모드가 항바이러스 면역 반응을 차단한다는 시험관 연구 및 클리닉 모두에서 좋은 증거가 있습니다. 따라서 우리는 많은 COVID-19 환자에서 관찰되는 면역 억제가 아필리모드에 의해 악화될 수 있음을 경고합니다.